Free tool
FAERS Monitor: Nourianz
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022075 or its brand name (Nourianz, Istradefylline). Reports on generic versions are filed under their own applications.
Reports
5,984
Serious
2,641
44% of reports
Hospitalization
783
Death reported
937
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death726
- drug ineffective634
- hallucination617
- dyskinesia484
- condition aggravated464
- dizziness423
- product dose omission issue363
- constipation357
- fall352
- tremor272
- therapy non-responder252
- insomnia229
- fatigue203
- nausea200
- parkinson^s disease185
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2014 | 4 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 5 |
| 2018 | 25 |
| 2019 | 133 |
| 2020 | 1,509 |
| 2021 | 1,206 |
| 2022 | 1,004 |
| 2023 | 610 |
| 2024 | 678 |
| 2025 | 599 |
| 2026 | 207 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,175 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| dyskinesiaSignal | 484 | 42.4 | 38.9 | 19,305 |
| hallucinationSignal | 617 | 29.0 | 26.9 | 16,578 |
| therapy non-responderSignal | 252 | 19.8 | 17.6 | 4,467 |
| tremorSignal | 272 | 5.8 | 5.1 | 1,074 |
| constipationSignal | 357 | 5.8 | 5.2 | 1,412 |
| condition aggravatedSignal | 464 | 5.4 | 4.9 | 1,668 |
| product dose omission issueSignal | 363 | 4.3 | 3.9 | 943 |
| fallSignal | 352 | 3.7 | 3.4 | 708 |
| insomniaSignal | 229 | 3.0 | 2.7 | 312 |
| dizzinessSignal | 423 | 3.0 | 2.7 | 568 |
| deathSignal | 726 | 3.0 | 2.8 | 982 |
| drug ineffective | 634 | 1.7 | 1.6 | 190 |
| fatigue | 203 | 0.9 | 0.8 | 2 |
| nausea | 200 | 0.9 | 0.8 | 3 |
| parkinson^s disease | 185 | 0.0 | 0.0 | 647,213 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.